Currently, mutations in KRAS exon 2 are routinely tested for metastatic CRC in most clinical institutions, and the identification of such mutations has been wildly reported to be associated with poor prognosis and resistance to anti-epidermal growth factor receptor (EGFR) therapy 3, 7, 8. Here, KRAS is linked to colorectal carcinoma.